Neuroinflammatory and Genetic Mechanisms Underlying Anxiety Disorders

Neuroinflammatory Pathophysiology

Individuals with anxiety disorders exhibit higher circulating levels of pro‑inflammatory cytokines (IL‑6, TNF‑α, IL‑1β, interferons) and chemokines (CCL2, CCL3, CCL5). This systemic inflammatory profile is consistently reported across studies. 1
Expression of danger‑associated molecular pattern (DAMP) receptors—including major histocompatibility complex (MHC) molecules and toll‑like receptors (TLRs)—is up‑regulated in anxiety. The heightened innate immune signaling contributes to chronic neuroinflammation. 2
Components of the NLRP3 inflammasome are elevated in people with anxiety, sustaining inflammatory cascades within the central nervous system. 2
Higher concentrations of C‑reactive protein (CRP), IL‑1β, and TNF‑α are associated with an increased risk of developing anxiety disorders. These biomarkers may serve as early indicators of vulnerability. 2

Comorbid anxiety is highly prevalent among individuals with chronic inflammatory conditions such as rheumatoid arthritis. Epidemiologic data suggest a bidirectional relationship between systemic inflammation and anxiety symptomatology. 2
Targeted monoclonal antibodies that neutralize pro‑inflammatory cytokines (e.g., sirukumab, siltuximab, infliximab, tocilizumab) have been shown to reduce anxiety symptoms when used to treat underlying inflammatory diseases. These findings arise from interventional studies in patients receiving cytokine‑blocking therapy. 2
Adjunctive treatment with cyclo‑oxygenase‑2 (COX‑2) inhibitors enhances remission rates of anxiety, particularly in individuals with elevated inflammatory markers. Randomized controlled trials support the benefit of anti‑inflammatory pharmacotherapy as a supplement to standard anxiety treatment. 2

Polymorphisms in genes encoding inflammatory mediators (IL‑1β, IL‑6, IL‑11) are linked to greater susceptibility to anxiety disorders and influence treatment response. Genetic association studies identify these variants as risk factors. 1
Chronic stress leads to reduced global DNA methylation in the prefrontal cortex and amygdala, reflecting epigenetic dysregulation that may perpetuate anxiety pathology. Epigenome‑wide analyses demonstrate this hypomethylation pattern. 3
Stress‑induced alterations in histone acetylation and expression of chromatin‑modifying enzymes have been documented, indicating dynamic epigenetic remodeling in anxiety‑related brain regions. These changes are observed in both animal models and human post‑mortem tissue. 4
The histone deacetylase gene HDAC5 plays a pivotal role in modulating anxiety‑related behaviors, as evidenced by functional studies manipulating HDAC5 activity. 3

Guidelines emphasize that anxiety disorders involve measurable biological dysfunction—including neuroinflammatory and neuroendocrine abnormalities—warranting medical intervention rather than being viewed solely as psychological distress. This perspective is supported by multiple sources. 1
Incorporating anti‑inflammatory strategies (e.g., cytokine‑targeted biologics, COX‑2 inhibitors) may be considered for patients with anxiety who exhibit elevated inflammatory biomarkers, aligning treatment with underlying pathophysiology. Evidence strength ranges from observational cohorts to randomized trials. 2

Chronic cortisol elevation in GAD creates a cascade of neurobiological changes including hippocampal volume reduction, prefrontal cortex dysfunction, amygdala hyperactivity, and systemic metabolic disruption that directly explains symptoms of poor sleep, muscle tension, and feeling on edge 5
Persistent HPA axis activation distinguishes chronic stress from adaptive acute stress responses, leading to sustained cortisol elevation that fundamentally alters brain structure and function 5

Hippocampal atrophy occurs with reduced volume and functionality, directly impairing memory formation and learning capacity 5
Decreased hippocampal neurogenesis means fewer new brain cells are generated in this critical memory center 5
Prefrontal cortex dysfunction with decreased connectivity to the amygdala reduces the brain's ability to regulate emotional responses—explaining why one feels "on edge" 5
Amygdala hyperactivity serves as an overactive alarm system, continuously triggering fight-or-flight responses 5, 6

The hyperactive amygdala activates sympathoexcitatory neural circuits, increasing catecholamine release that directly causes muscle tension 6
Elevated cortisol levels, particularly in the presleep and early sleep period, directly interfere with sleep initiation and maintenance 7
Physiological hyperarousal with increased 24-hour metabolic rate and elevated fast (waking) EEG activity during sleep prevents restorative rest 7
Autonomic nervous system dysregulation leads to persistent fight-or-flight responses 5

Chronic stress induces "dysmetabolism" or metabolic remodeling in the brain 5
Disturbed energy generation with deficient mitochondrial function 5
Insulin resistance and compensatory hyperinsulinemia develop as direct consequences 5
Activated microglia (brain immune cells) produce chronic inflammation 5
Elevated pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) contribute to both anxiety and depressive symptoms 5

Depression has been associated with hypercortisolemia, heightened catecholamines, increased heart rate, and altered vagal control—all cardiovascular risk factors 8
The structural and functional brain changes significantly increase risk for developing comorbid depression 5
Chronic stress exacerbates psychological problems and can contribute to chronic pain syndromes 5

Relaxation techniques and environmental enrichment can help counteract negative brain effects, though these should complement rather than replace evidence-based treatments 5
Safe, stable, nurturing relationships buffer adversity and promote resilience against chronic stress effects 5